The deal shows how quickly drugmakers are moving to AI to speed discovery, and why the race now touches capital, timelines, and competitive advantage.

A Science study says bumblebees can tackle a box-and-banana style puzzle on their own, a clue that even tiny-brained creatures may handle novel tasks without being taught.

The quantum computing company chose a traditional IPO over the SPAC-heavy path, signaling a bid for mainstream credibility that other founders and boards will be watching closely.

The startup's physics simulation platform aims to close the gap between molecular structure and real-world behavior, a blind spot that costs pharma and materials companies billions.